Karolinska Development AB is a high-risk diversified financial company based in Sweden. With an ESG score of 37.9, it specializes in investing in life science innovations in the Nordic region. The company focuses on identifying and developing breakthrough medical innovations with the goal of achieving a return on investment. Key profiles include Aprea Therapeutics, Modus Therapeutics, BioArctic, Umecrine Cognition, and OssDsign.